Mostrar el registro sencillo del ítem
dc.contributor.author | Arranz Sanz, Eduardo | |
dc.date.accessioned | 2014-02-06T16:48:49Z | |
dc.date.available | 2014-02-06T16:48:49Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Gut, vol.000, n.000. p.1-2 | es |
dc.identifier.uri | http://uvadoc.uva.es/handle/10324/4240 | |
dc.description | Producción Científica | es |
dc.description.abstract | Prolyl-endopeptidase supplementation has been proposed to favour gliadin degradation as an alternative treatment for coeliac disease (CD), although the real usefulness of this therapy in vivo is still under discussion. 1 However, our data point to alternative treatments aiming to modify the intestinal microbiota in patients with CD by the use of probiotics and/or prebiotics. We propose that the induction of gliadin proteolysis in the human gut might not be the solution but the origin of CD. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | spa | es |
dc.publisher | Instituto de Biología y Genética Molecula (IBGM) | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Enfermedad celíaca | es |
dc.title | Is it true that coeliacs do not digest gliadin?. Degradation pattern of gliadin in coeliac disease small intestinal mucosa | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | 10.1136/gut 2008-167296 | es |
dc.identifier.publicationfirstpage | 1 | es |
dc.identifier.publicationissue | 0 | es |
dc.identifier.publicationlastpage | 2 | es |
dc.identifier.publicationtitle | Gut | es |
dc.identifier.publicationvolume | 0 | es |
dc.peerreviewed | SI | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International